Takeda Pharmaceuticals, a Japanese drugmaker, is exploring the options of conducting global clinical trials in India to accelerate the launch of its innovative drugs in the world's most populous nation, its India head told Reuters.
"India is a strategic growth market for Takeda, and we are making significant long-term investments... in terms of innovation and building capabilities," said Annapurna Das, the general manager of Takeda's India operations.
"We're exploring the opportunity of leveraging India's clinical trial ecosystem," she added.
The company is also open to partnering with local academia, healthcare providers and technology firms in India for innovation, the general manager shared. "At this point of time, we are still kind of exploring and evaluating how we want to go ahead."
What are Takeda's plans in India?
Takeda aims to integrate India's research and development "ecosystem" into its global pipeline and expand the Indian patients' access to cutting-edge therapies in oncology, neuroscience, gastrointestinal health and inflammation.
The drugmaker also aims to launch key cancer drugs over the next 2-3 years in India, with a lung cancer drug ready to hit the shelves this year.
It has tied up with a local vaccine maker Biological E., to create a dengue vaccine that is awaiting its approval from the country's drug regulator. Additionally, Takeda also set up an innovation centre in Bengaluru earlier this year to tap the country's tech talent to power its global digital transformation. The centre is expanding from a current staff of 500 to 750 people working in the fields of AI, data science, engineering and design.
Powered by various patient pools, cost efficiency and a fast-growing hospital network, India's clinical trials market is booming and gaining international attention rapidly. Grand View Research expects the market to exceed $2 billion by 2030.
"India is a strategic growth market for Takeda, and we are making significant long-term investments... in terms of innovation and building capabilities," said Annapurna Das, the general manager of Takeda's India operations.
"We're exploring the opportunity of leveraging India's clinical trial ecosystem," she added.
The company is also open to partnering with local academia, healthcare providers and technology firms in India for innovation, the general manager shared. "At this point of time, we are still kind of exploring and evaluating how we want to go ahead."
What are Takeda's plans in India?
Takeda aims to integrate India's research and development "ecosystem" into its global pipeline and expand the Indian patients' access to cutting-edge therapies in oncology, neuroscience, gastrointestinal health and inflammation.
The drugmaker also aims to launch key cancer drugs over the next 2-3 years in India, with a lung cancer drug ready to hit the shelves this year.
It has tied up with a local vaccine maker Biological E., to create a dengue vaccine that is awaiting its approval from the country's drug regulator. Additionally, Takeda also set up an innovation centre in Bengaluru earlier this year to tap the country's tech talent to power its global digital transformation. The centre is expanding from a current staff of 500 to 750 people working in the fields of AI, data science, engineering and design.
Powered by various patient pools, cost efficiency and a fast-growing hospital network, India's clinical trials market is booming and gaining international attention rapidly. Grand View Research expects the market to exceed $2 billion by 2030.
You may also like
Cash in chips bag row: NYC mayor Adam's ex-aide calls it 'birthday gift'; says 'reporter tried to hurt me'
'False and misleading': Government says hasn't issued any unblocking order for TikTok - what we know
Morgan Gibbs-White breaks silence on failed Tottenham transfer after Nottingham Forest decision
Fury in Tenerife as travel platform names crowded spot 'most photogenic place' in Spain
Ultrahuman Sues Oura Over Alleged Smart Ring Patent Infringement
